J.P. Morgan Reiterates a Buy Rating on ​Novo Nordisk (NVO)

​Novo Nordisk A/S (NYSE:NVO) is one of the Best Very Cheap Stocks to Invest In. On November 24, Richard Vosser from J.P. Morgan reiterated a Buy rating on the stock without disclosing any price targets. Earlier on November 17, Evan Seigerman from BMO Capital had reiterated a Hold rating on the stock and also lowered the price target from $55 to $50.

​Previously, on November 17, CNN reported that Novo Nordisk A/S (NYSE:NVO) announced further lowering the prices for its weight loss drugs for cash-paying customers. The company has been facing pressure from the US administration due to lower the prices. After the price reduction, the company is now offering the first two monthly doses of Wegovy and Ozempic for $199 for cash-paying patients. This discount will expire at the end of March.

​Furthermore, Novo Nordisk A/S (NYSE:NVO) has also reduced the prices of its weight loss and diabetes drugs for other self-pay patients to $349 a month, down from $499 a month.

​​Novo Nordisk A/S (NYSE:NVO) is a global healthcare company focused mainly on diabetes and obesity care.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.